Skip to content

Released Nov 13, 2019, after the close

10-Q filed Nov 13, 2019, 44 days after period end · 0001213900-19-023231

Q3 2019 · 10-Q
Revenue—
Net Income-$8.55Mno prior Q3 2018 on fileN/M vs Q2 2019
EPS Diluted-$1.27no prior Q3 2018 on fileN/M vs Q2 2019
Operating Income-$8,383,000—
Operating Cash Flowderived-$6,704,000—
Free Cash Flowderived-$6,731,000—

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

no prior Q3 2018 on file

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Compass Therapeutics, Inc. · CIK 1738021 · Engraved from SEC EDGAR